Evidence mapPaperPMID 41667648Full record

ReviewNature reviews. Nephrology2026

Optimal patient care in advanced chronic kidney disease progressing to kidney failure.

Christian Combe, Natalia Alencar de Pinho, Murilo Guedes, Luc Frimat, Denis Fouque, Sophie Liabeuf, Abdou Niang, Talerngsak Kanjanabuch, Bénédicte Stengel, Ziad A Massy and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Christian CombeBordeaux School of Public Health, Université de Bordeaux, INSERM U1219, CIC 1401, Bordeaux, France. christian.combe@u-bordeaux.fr.ORCID http://orcid.org/0000-0002-0360-573X
Natalia Alencar de PinhoCentre for Research in Epidemiology and Population Health (CESP), Paris-Saclay University, Versailles Saint Quentin University, INSERM U1018, Clinical Epidemiology and Pharmacoepidemiology Team, Villejuif, France.
Murilo GuedesSchool of Medicine and Life Sciences, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil.
Luc FrimatDepartment of Nephrology, UMR 1319 INSPIIRE, Université de Lorraine, INSERM, Nancy, France.
Denis FouqueDepartment of Nephrology and Nutrition, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.ORCID http://orcid.org/0000-0002-9707-7199
Sophie LiabeufDepartment of Clinical Pharmacology, Amiens University Hospital, Amiens, France.
Abdou NiangCheikh Anta Diop University of Dakar, Nephrology department, Dakar, Sénégal.ORCID http://orcid.org/0000-0002-4025-0990
Talerngsak KanjanabuchDivision of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.ORCID http://orcid.org/0000-0002-2996-8934
Bénédicte StengelCentre for Research in Epidemiology and Population Health (CESP), Paris-Saclay University, Versailles Saint Quentin University, INSERM U1018, Clinical Epidemiology and Pharmacoepidemiology Team, Villejuif, France.
Ziad A MassyCentre for Research in Epidemiology and Population Health (CESP), Paris-Saclay University, Versailles Saint Quentin University, INSERM U1018, Clinical Epidemiology and Pharmacoepidemiology Team, Villejuif, France.
Roberto Pecoits-FilhoSchool of Medicine and Life Sciences, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The transition from advanced chronic kidney disease (CKD) to kidney failure requires comprehensive management to optimize patient outcomes. This crucial period, in practical terms defined by CKD stages G4 and G5, involves complex decision-making regarding kidney replacement therapy, pre-emptive kidney transplantation and conservative kidney management. Patient preferences, quality of life, and comorbidities, especially cardiovascular disease, are essential considerations when making treatment decisions. Importantly, nephroprotective therapies should be continued even at advanced stages of CKD to stabilize kidney function and prevent cardiovascular events. Pre-emptive kidney transplantation, when feasible, offers the best outcomes and should be prioritized. Dialysis initiation should be based on clinical symptoms and shared decision-making with the patient, rather than laboratory values alone. For some, particularly older, patients with substantial comorbidities, conservative kidney management, emphasizing symptom management without kidney replacement therapy, might be preferred. Considerable disparities in access to care exist globally, especially in low- and middle-income countries, highlighting the need for tailored strategies. Registry and cohort studies have provided most of the scientific understanding in this area, but more randomized clinical trials are needed to guide advanced CKD management.

Indexed as

Kidney Failure, ChronicRenal Insufficiency, ChronicDisease ProgressionHumansKidney TransplantationQuality of LifeRenal DialysisRenal Replacement Therapy

Identifiers

PMID41667648

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.